Abstract
Introduction This study aimed to produce community-level geo-spatial mapping of confirmed COVID-19 cases in Ontario, Canada in near real-time to support decision-making. This was accomplished by area-to-area geostatistical analysis, space-time integration, and spatial interpolation of COVID-19 positive individuals.
Methods COVID-19 cases and locations were curated for geostatistical analyses from March 2020 through June 2021, corresponding to the first, second, and third waves of infections. Daily cases were aggregated according to designated forward sortation area [FSA], and postal codes [PC] in municipal regions covering Hamilton, Kitchener/Waterloo, London, Ottawa, Toronto, and Windsor/Essex county. Hotspots were identified with area-to-area tests including Getis-Ord Gi*, Global Moran’s I spatial autocorrelation, and Local Moran’s I asymmetric clustering and outlier analyses. Case counts were also interpolated across geographic regions by Empirical Bayesian Kriging, which localizes high concentrations of COVID-19 positive tests, independent of FSA or PC boundaries. The Geostatistical Disease Epidemiology Toolbox, which is freely-available software, automates the identification of these regions and produces digital maps for public health professionals to assist in pandemic management of contact tracing and distribution of other resources.
Results/Discussion This study provided indicators in real-time of likely, community-level disease transmission through innovative geospatial analyses of COVID-19 incidence data. Municipal and provincial results were validated by comparisons with known outbreaks at long-term care and other high density residences and on farms. PC-level analyses revealed hotspots at higher geospatial resolution than public reports of FSAs, and often sooner. Results of different tests and kriging were compared to determine consistency among hotspot assignments. Concurrent or consecutive hotspots in close proximity suggested potential community transmission of COVID-19 from cluster and outlier analysis of neighboring PCs and by kriging. Results were also stratified by population based-categories (sex, age, and presence/absence of comorbidities). Earlier recognition of hotspots could reduce public health burdens of COVID-19 and expedite contact tracing.
Competing Interest Statement
PKR cofounded and BCS and EJM are employees of CytoGnomix Inc.
Funding Statement
Data acquisition and computing facilities used in this study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH) and the Ministry of Long-Term Care (MLTC). Data and information compiled were also provided by MOH. This study was also supported by the Ontario Health Data Platform (OHDP), a Province of Ontario initiative to support Ontario's ongoing response to COVID-19 and its related impacts. The work described was funded and performed under a contribution agreement between the Innovation for Defence Excellence and Security (IDEaS) program at the Department of National Defence and CytoGnomix. The analyses, conclusions, opinions and statements expressed herein are solely those of the authors and do not reflect those of the funding or data sources. No endorsement by ICES, OHDP, its partners, or the Province of Ontario is intended or should be inferred.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Access to anonymized Ontario COVID-19 test results through the ICES Research and Analytic Environment (RAE) was obtained through Applied Health Research Questions (AHRQ) project #P0950.096 approved by the Ontario Ministry of Health and Long-Term Care (MOHLTC). ICES has been designated to receive and use data under the province's Personal Health Information Protection Act. All authors have completed privacy training and signed a data access agreement with ICES.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
A data repository Zenodo Archive has been created for this study. However, this archive does not provide complete COVID-19 case counts. To ensure patient privacy, ICES stipulated that the counts in all regions (FSAs or postal codes) exhibiting between 1 and 5 daily COVID-19 cases be masked. Therefore, all case counts between 1-5 will appear as NA within the files of this archive. To obtain access to the complete dataset, you will be required to apply to ICES directly (https://www.ices.on.ca/).
